Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation

Cell Cycle

Volumn 11, Issue 7, 2012, Pages 1374-1382

  Sikka, Arron ^a   Kaur, Manjinder ^a   Agarwal, Chapla ^a,b   Deep, Gagan ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cell cycle arrest; Cell viability; Chemoprevention; Growth inhibition; Head and neck cancer; Metformin

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLIN E; INITIATION FACTOR 4E BINDING PROTEIN 1; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; DRUG EFFICACY; DRUG MECHANISM; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TRANSLATION REGULATION;

NICOTIANA TABACUM;

EID: 84860317111     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19798     Document Type: Article

References (58)

1. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999; 16:273-81; PMID:10220200; http://dx.doi.org/10.1046/j.1464-5491.1999.00006.x.
2. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22:925-7; PMID:10372243; http://dx.doi. org/10.2337/diacare.22.6.925.
3. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Metformin in polycystic ovary syndrome. Ann NY Acad Sci 2010; 1205:192-8; PMID:20840272; http://dx.doi.org/10.1111/j.1749-6632.2010.05679.x.
4. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32:1743-5; PMID:19502540; http://dx.doi.org/10.2337/dc09-0258.
5. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2011; PMID:21301998; http://dx.doi.org/10.1007/s12032-011-9846- 7.
6. Grisouard J, Timper K, Radimerski TM, Frey DM, Peterli R, Kola B, et al. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol 2010; 80:1736-45; PMID:20816671; http://dx.doi.org/10.1016/j.bcp.2010.08.021.
7. Kuhajda FP. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond) 2008; 32:36-41; PMID:18719597; http://dx.doi.org/10.1038/ijo.2008.121.
8. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458:1056-60; PMID:19262508; http://dx.doi.org/10. 1038/nature07813.
9. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196:65-80; PMID:19245654; http:// dx.doi.org/10.1111/j.1748-16.2009.01972.x.
10. Samson DJ, Ratko TA, Rothenberg BM, Brown HM, Bonnell CJ, Ziegler KM, et al. Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer. Rockville (MD) 2010.
11. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer - Part 1: Epidemiology, presentation and prevention. BMJ 2010; 341:4684; PMID:20855405; http://dx.doi.org/10.1136/bmj.c4684.
12. Otto SE. Oncology Nursing. London: Mosby 2001.
13. Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus- related head and neck tumors: clinical and research implication. Curr Opin Oncol 2009; 21:201- 5; PMID:19370803; http://dx.doi.org/10.1097/ CCO.0b013e328329ab64.
14. Mehanna H, West CM, Nutting C, Paleri V. Head and neck cancer - Part 2: Treatment and prognostic factors. BMJ 2010; 341:4690; PMID:20876637; http://dx.doi. org/10.1136/bmj.c4690.
15. Urba SG, Wolf GT, Bradford CR, Thornton AF, Eisbruch A, Terrell JE, et al. Neoadjuvant therapy for organ preservation in head and neck cancer. Laryngoscope 2000; 110:2074-80; PMID:11129024; http://dx.doi.org/10.1097/ 00005537-200012000-00019.
16. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8:885-92; PMID:11895923.
17. Chowdhury TA. Diabetes and cancer. QJM 2010; 103:905-15; PMID:20739356; http://dx.doi.org/10.1093/qjmed/hcq149.
18. Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 2010; 16:4313-8; PMID:20647474; http://dx.doi.org/10.1158/1078-0432.CCR-09-1942.
19. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis. Cancer Prev Res (Phila) 2010; 3:1451-61; PMID:20947488; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157.
20. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010; 3:1066-76; PMID:20810672; http:// dx.doi.org/10.1158/1940- 6207.CAPR-10-0055.
21. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends lifespan of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188- 97; PMID:20016287; http://dx.doi.org/10.4161/cc.9.1. 10407.
22. Bojkova B, Orendas P, Garajova M, Kassayova M, Kutna V, Ahlersova E, et al. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009; 56:269-74; PMID:19309231; http://dx.doi. org/10.4149/neo-2009-03-269.
23. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, et al. If started early in life, metformin treatment increases lifespan and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3:148-57; PMID:21386129.
24. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253-67; PMID:18354415; http://dx.doi. org/10.1038/nrc2347.
25. Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J. Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother 2001; 5:109-29; PMID:11355576; http://dx.doi.org/10. 1016/S1278-3218(01)00087-7.
26. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and betaTrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8:438-49; PMID:18500245; http://dx.doi.org/10.1038/nrc2396.
27. Ekim B, Magnuson B, Acosta-Jaquez HA, Keller JA, Feener EP, Fingar DC. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth and cell cycle progression. Mol Cell Biol 2011; 31:2787-801; PMID:21576368; http://dx.doi. org/10.1128/MCB.05437-11.
28. White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. Mol Oncol 2009; 3:402-8; PMID:19546037; http:// dx.doi.org/10.1016/j.molonc.2009.05.003.
29. Wehage IC, Fansa H. Complex reconstructions in head and neck cancer surgery: decision making. Head Neck Oncol 2011; 3:14; PMID:21385421; http://dx.doi. org/10.1186/1758-3284-3-14.
30. Chu PY, Chang SY. Reconstruction of the hypopharynx after surgical treatment of squamous cell carcinoma. J Chin Med Assoc 2009; 72:351-5; PMID:19581140; http://dx.doi.org/10.1016/S1726-4901(09)70386-7.
31. Boudreaux BA, Rosenthal EL, Magnuson JS, Newman JR, Desmond RA, Clemons L, et al. Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg 2009; 135:397-401; PMID:19380364; http://dx.doi.org/10.1001/ archoto.2009.24.
32. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras- Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527.
33. Menendez JA, Cufí S, Oliveras-Ferraros C, Martin- Castillo B, Joven J, Vellon L, et al. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3:1063-77; PMID:22170748.
34. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760-74; PMID:21084729.
35. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the antidiabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011; 10:1144-51; PMID:21368581; http://dx.doi.org/10.4161/cc.10.7.15210.
36. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin- Castillo B, Joven J, Menendez JA. Metformin against TGFβ-induced epithelial-to- mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010; 9:4461-8; PMID:21088486; http://dx.doi.org/10.4161/ cc.9.22.14048.
37. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057-64; PMID:20305377; http://dx.doi.org/10.4161/ cc.9.6.10994.
38. Korc M. Smad4: gatekeeper gene in head and neck squamous cell carcinoma. J Clin Invest 2009; 119:3208-11; PMID:19841540.
39. Perez-Ordoñez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006; 59:445-53; PMID:16644882; http://dx.doi.org/10.1136/jcp.2003.007641.
40. Morris LG, Chan TA. Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancer. Oncotarget 2011; 2:894-5; PMID:22248868.
41. Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011; 2:599-609; PMID:21865609.
42. Fukuchi M, Masuda N, Miyazaki T, Nakajima M, Osawa H, Kato H, et al. Decreased Smad4 expression in the transforming growth factorbeta signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 2002; 95:737-43; PMID:12209716; http://dx.doi.org/10.1002/cncr.10727.
43. Medrano EE. Repression of TGFbeta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival and metastasis. Oncogene 2003; 22:3123-9; PMID:12793438; http:// dx.doi.org/10.1038/sj.onc. 1206452.
44. Xie W, Bharathy S, Kim D, Haffty BG, Rimm DL, Reiss M. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res 2003; 14:61-73; PMID:14649540.
45. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999; 287:821-8; PMID:10222191; http://dx.doi. org/10.1006/jmbi.1999.2640.
46. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213:138-49; PMID:8931660.
47. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9:33; PMID:21470407; http://dx.doi. org/10.1186/1741-7015-9-33.
48. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576-86; PMID:18212742; http://dx.doi. org/10.1038/sj.onc.1211024.
49. Tosca L, Ramé C, Chabrolle C, Tesseraud S, Dupont J. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. Reproduction 2010; 139:409-18; PMID:19906888; http://dx.doi. org/10.1530/REP-09-0351.
50. Chan CH, Lee SW, Wang J, Lin HK. Regulation of Skp2 expression and activity and its role in cancer progression. Scientific World Journal 2010; 10:1001-15; PMID:20526532; http://dx.doi.org/10.1100/tsw.2010.89.
51. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitinmediated control of oncogene and tumor suppressor gene products. Cancer Sci 2009; 100:1374-81; PMID:19459846; http://dx.doi.org/10.1111/j.1349-7006.2009.01196.x.
52. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 2005; 16:323-33; PMID:15840441; http:// dx.doi.org/10.1016/j.semcdb.2005.02.010.
53. Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 2010; 285:9780-91; PMID:20093366; http://dx.doi. org/10.1074/jbc.M109.065466.
54. Liao YM, Kim C, Yen Y. Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol 2011; 3:22; PMID:21513566; http:// dx.doi.org/10.1186/1758-3284-3-22.
55. Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972; 29:117-21; PMID:4332311; http://dx.doi. org/10.1002/1097- 0142(197201)29:1<117::AIDCNCR2820290119> 3.0.CO;2-R.
56. Peterson WD Jr, Stulberg CS, Simpson WF. A permanent heteroploid human cell line with type B glucose- 6-phosphate dehydrogenase. Proc Soc Exp Biol Med 1971; 136:1187-91; PMID:5554463.
57. Kaur M, Singh RP, Gu M, Agarwal R, Agarwal C. Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin Cancer Res 2006; 12:6194-202; PMID:17062697; http://dx.doi. org/10.1158/1078-0432.CCR- 06-1465.
58. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, et al. Aurora kinases A and B are upregulated by Myc and are essential for maintenance of the malignant state. Blood 2010; 116:1498-505; PMID:20519624; http://dx.doi.org/10.1182/blood-2009-11-251074.